Methadone in the treatment of neuropathic pain

Bruno Gagnon, Abdulaziz Almahrezi, Gil Schreier

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Methadone, being an N-Methyl-D-Aspartate receptor antagonist, may have a potential role in the treatment of neuropathic pain. Objectives: To evaluate the effect of methadone in the treatment of neuropathic pain and to estimate the possible dose ranges needed for pain control. Methods: Methadone was offered as a treatment option to consecutive cancer and noncancer patients with neuropathic pain. Pain intensity was measured by the visual analogue scale (VAS) (0-10 cm where 0 = no pain and 10 = worst possible pain). Mechanical allodynia and paroxysmal (shooting) pain were assessed clinically. All assessments were collected prospectively before treatment and once a stable dose of methadone was reached. Results: A total number of 18 patients met our inclusion criteria. The mean pretreatment VAS ± SD was 7.7±1.5 cm and this dropped significantly to 1.4±1.7 cm on a stable dose of methadone (P

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalPain Research and Management
Volume8
Issue number3
Publication statusPublished - Sep 2003

Fingerprint

Methadone
Neuralgia
Pain
Visual Analog Scale
Therapeutics
Hyperalgesia
N-Methyl-D-Aspartate Receptors
Neoplasms

Keywords

  • Cancer pain
  • Methadone
  • Neurophathic pain
  • Opioids

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Methadone in the treatment of neuropathic pain. / Gagnon, Bruno; Almahrezi, Abdulaziz; Schreier, Gil.

In: Pain Research and Management, Vol. 8, No. 3, 09.2003, p. 149-154.

Research output: Contribution to journalArticle

Gagnon, B, Almahrezi, A & Schreier, G 2003, 'Methadone in the treatment of neuropathic pain', Pain Research and Management, vol. 8, no. 3, pp. 149-154.
Gagnon, Bruno ; Almahrezi, Abdulaziz ; Schreier, Gil. / Methadone in the treatment of neuropathic pain. In: Pain Research and Management. 2003 ; Vol. 8, No. 3. pp. 149-154.
@article{b63d800843fd4020a818d2ef2d8bcadd,
title = "Methadone in the treatment of neuropathic pain",
abstract = "Background: Methadone, being an N-Methyl-D-Aspartate receptor antagonist, may have a potential role in the treatment of neuropathic pain. Objectives: To evaluate the effect of methadone in the treatment of neuropathic pain and to estimate the possible dose ranges needed for pain control. Methods: Methadone was offered as a treatment option to consecutive cancer and noncancer patients with neuropathic pain. Pain intensity was measured by the visual analogue scale (VAS) (0-10 cm where 0 = no pain and 10 = worst possible pain). Mechanical allodynia and paroxysmal (shooting) pain were assessed clinically. All assessments were collected prospectively before treatment and once a stable dose of methadone was reached. Results: A total number of 18 patients met our inclusion criteria. The mean pretreatment VAS ± SD was 7.7±1.5 cm and this dropped significantly to 1.4±1.7 cm on a stable dose of methadone (P",
keywords = "Cancer pain, Methadone, Neurophathic pain, Opioids",
author = "Bruno Gagnon and Abdulaziz Almahrezi and Gil Schreier",
year = "2003",
month = "9",
language = "English",
volume = "8",
pages = "149--154",
journal = "Pain Research and Management",
issn = "1203-6765",
publisher = "Pulsus Group Inc.",
number = "3",

}

TY - JOUR

T1 - Methadone in the treatment of neuropathic pain

AU - Gagnon, Bruno

AU - Almahrezi, Abdulaziz

AU - Schreier, Gil

PY - 2003/9

Y1 - 2003/9

N2 - Background: Methadone, being an N-Methyl-D-Aspartate receptor antagonist, may have a potential role in the treatment of neuropathic pain. Objectives: To evaluate the effect of methadone in the treatment of neuropathic pain and to estimate the possible dose ranges needed for pain control. Methods: Methadone was offered as a treatment option to consecutive cancer and noncancer patients with neuropathic pain. Pain intensity was measured by the visual analogue scale (VAS) (0-10 cm where 0 = no pain and 10 = worst possible pain). Mechanical allodynia and paroxysmal (shooting) pain were assessed clinically. All assessments were collected prospectively before treatment and once a stable dose of methadone was reached. Results: A total number of 18 patients met our inclusion criteria. The mean pretreatment VAS ± SD was 7.7±1.5 cm and this dropped significantly to 1.4±1.7 cm on a stable dose of methadone (P

AB - Background: Methadone, being an N-Methyl-D-Aspartate receptor antagonist, may have a potential role in the treatment of neuropathic pain. Objectives: To evaluate the effect of methadone in the treatment of neuropathic pain and to estimate the possible dose ranges needed for pain control. Methods: Methadone was offered as a treatment option to consecutive cancer and noncancer patients with neuropathic pain. Pain intensity was measured by the visual analogue scale (VAS) (0-10 cm where 0 = no pain and 10 = worst possible pain). Mechanical allodynia and paroxysmal (shooting) pain were assessed clinically. All assessments were collected prospectively before treatment and once a stable dose of methadone was reached. Results: A total number of 18 patients met our inclusion criteria. The mean pretreatment VAS ± SD was 7.7±1.5 cm and this dropped significantly to 1.4±1.7 cm on a stable dose of methadone (P

KW - Cancer pain

KW - Methadone

KW - Neurophathic pain

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=0344468131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344468131&partnerID=8YFLogxK

M3 - Article

C2 - 14657982

AN - SCOPUS:0344468131

VL - 8

SP - 149

EP - 154

JO - Pain Research and Management

JF - Pain Research and Management

SN - 1203-6765

IS - 3

ER -